EarlyCDT-Lung is a simple blood test to aid in the risk assessment and early detection of lung cancer.
Early in the development of a solid tumour cancer, the body mounts an immune response to certain by-products, or proteins called tumour antigens from cancer cells, by producing autoantibodies. These autoantibodies can rise in the earliest stages of cancer and can be measured in an individuals blood. EarlyCDT-Lung has been developed to measure a panel of 7 autoantibodies associated specifically with lung cancer.
The test has been developed so that individuals, at high risk of developing lung cancer, can benefit from an increasing chance that lung cancer can be detected at the earliest possible stages, when treatment can be most successful. It can also be used along with imaging such as chest X-rays and CT scans to further assess the risk of lung cancer being present.